| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d42cde6b227c9ba84864f52e971057a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 |
| filingDate |
2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33a4154efa9ebc61e385406660f0c863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ebbbf38c53a36b716953cf3c6914047 |
| publicationDate |
2022-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114621211-A |
| titleOfInvention |
Crystal form of Lanifibranor and its preparation method and use |
| abstract |
Provide a new crystal form of Lanifibranor (referred to as "Compound I") and its preparation method, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of pan-PPAR agonist drugs and drugs for the treatment of nonalcoholic steatohepatitis use. The provided new crystal form of compound I has one or more improved properties than the prior art, solves the problems existing in the prior art, and has important value for the optimization and development of medicines containing compound I. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023016319-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022258060-A1 |
| priorityDate |
2020-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |